Acceleron  

Publications

  • Publication
    Luspatercept
    Dec 5, 2016
    Luspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. ASH 2016; December 6th, 2017.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results From Phase 2 Studies
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Beta-Thalassemia: Preliminary Results From Phase 2 Studies
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Nov 11, 2016
    Luspatercept Posters at the 2016 TIF 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies; November 11-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 12, 2016
    Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 11, 2016
    Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 10, 2016
    RAP-536 (Murine Analog of ACE-536/Luspatercept) Inhibits SMAD2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in a Murine Model of Beta-Thalassemia; 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 10, 2016
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low- Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE‐MDS Study; 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 6, 2015
    Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 5, 2015
    Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. The 57th Annual American Society of Hematology; December...
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 13, 2015
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk MDS: Preliminary Results from the Phase 2 PACE-MDS Study. 20th Congress of the European Hematology Association; June 13, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 12, 2015
    Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Liver Iron Concentration in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 20th Congress of the European Hematology Association; June 12, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    May 2, 2015
    Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. 13th International Symposium on Myelodysplastic Syndromes (MDS), May 2, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 8, 2014
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results from a Phase 2 Study. 56th Annual American Society of Hematology Annual Meeting and Exposition; December 8, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 8, 2014
    Modified ActRIIB-mFc Fusion Protein Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease. 56th Annual American Society of Hematology Annual Meeting and Exposition; December 8, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2014
    Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 56th American Society of Hematology Annual Meeting and Exposition; December 7, 2014.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 19, 2014
    Modified Activin Receptor IIB Ligand Trap Mitigates Ineffective Erythropoiesis and Disease Complications in Murine Beta-Thalassemia. Blood 2014; 123(25):3864-3872
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 13, 2014
    Modified ActRIIB-Fc Fusion Protein (ACE-536) Decreases Irreversible Sickle Cells in a Murine Model of Sickle Cell Disease . European Hematology Associtation 19th Congress; June 13, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Apr 26, 2014
    A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers. American Journal of Hematology; published online April 26, 2014
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Apr 17, 2014
    Targeting a New Regulator of Erythropoiesis to Alleviate Anemia. Nature Medicine. April 2014; 20(4):334-35
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Mar 25, 2014
    Transforming Growth Factor-β Superfamily Ligand Trap ACE-536 Corrects Anemia by Promoting Late-Stage Erythropoiesis. Nature Medicine 2014; published online March 23, 2014
    + VIEW FULL Publication